How Can Epidemiology Help Optimize Anti-VEGF Therapy?
Epidemiology can play a crucial role in optimizing Anti-VEGF therapy by:
Identifying Population Disparities: Epidemiological studies can help identify disparities in access and outcomes, guiding targeted interventions. Evaluating Effectiveness: Long-term studies can evaluate the real-world effectiveness of Anti-VEGF agents, informing clinical guidelines. Monitoring Adverse Effects: Surveillance systems can monitor and report adverse effects, ensuring patient safety. Guiding Policy Decisions: Data-driven insights can inform healthcare policies to improve access and affordability of Anti-VEGF therapies.